United Therapeutics Co. (NASDAQ:UTHR) COO Michael Benkowitz Sells 10,000 Shares

United Therapeutics Co. (NASDAQ:UTHR) COO Michael Benkowitz sold 10,000 shares of the company’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $348.06, for a total value of $3,480,600.00. Following the completion of the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $896,950.62. This trade represents a 79.51 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Michael Benkowitz also recently made the following trade(s):

• On Monday, February 3rd, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $353.64, for a total transaction of $3,536,400.00.
• On Monday, January 27th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $370.71, for a total transaction of $3,707,100.00.
• On Tuesday, January 21st, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $364.91, for a total value of $3,649,100.00.
• On Monday, January 13th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $364.62, for a total transaction of $3,646,200.00.
• On Monday, December 30th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $356.68, for a total transaction of $3,566,800.00.
• On Monday, December 23rd, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $361.95, for a total transaction of $3,619,500.00.
• On Monday, November 25th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $372.75, for a total transaction of $3,727,500.00.

United Therapeutics Price Performance

NASDAQ:UTHR opened at $370.74 on Thursday. The firm has a market cap of $16.55 billion, a price-to-earnings ratio of 16.28, a price-to-earnings-growth ratio of 0.92 and a beta of 0.57. United Therapeutics Co. has a 1-year low of $211.61 and a 1-year high of $417.82. The firm’s fifty day moving average price is $361.99 and its 200 day moving average price is $358.32.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. UBS Group boosted their target price on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research note on Wednesday, January 8th. StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 16th. Argus raised their target price on United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. LADENBURG THALM/SH SH upped their price target on United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Finally, HC Wainwright raised their price objective on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. One analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $382.08.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Newbridge Financial Services Group Inc. purchased a new stake in United Therapeutics in the 4th quarter valued at approximately $25,000. Brooklyn Investment Group purchased a new stake in shares of United Therapeutics in the third quarter valued at approximately $33,000. Millstone Evans Group LLC acquired a new position in United Therapeutics during the fourth quarter worth $67,000. Capital Performance Advisors LLP purchased a new position in United Therapeutics in the third quarter worth $82,000. Finally, MassMutual Private Wealth & Trust FSB lifted its holdings in United Therapeutics by 31.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock valued at $85,000 after acquiring an additional 58 shares during the period. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.